Enavate Sciences

Enavate Sciences, established in 2022 and based in New York, is a private equity firm focused on the life sciences sector. The firm specializes in investing in innovative therapeutic and enabling technology companies, targeting both pre-clinical and clinical-stage enterprises. Enavate Sciences is dedicated to fostering the strategic growth of its portfolio companies, aiming to advance developments in therapeutic and technological solutions within the life sciences industry.

James Boylan

CEO

Christine Del Corsano

CFO

Edd Fleming

Executive Vice President, Commercialization

Robert Glassman

EVP, Search and Evaluation

Sara Nayeem

Executive Vice President, Investments

1 past transactions

CAMP4

Series B in 2022
CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.